| |
| |
|
| Insider
Information: |
Kirchgraber Paul R |
| Relationship: |
CEO, Covance Drug Deve... |
| City: |
Burlington |
| State: |
NC |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
12,946 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,726,298 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
12,946 |
|
|
| Total
Value |
$2,726,298 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Laboratory Corp of America |
LH |
CEO, Covance Drug Deve... |
2023-05-19 |
12,946 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
41 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug DevelopmentO |
• – – |
2019-11-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,407 |
|
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-02-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
337 |
4,744 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-02-07 |
4 |
D |
$182.33 |
$18,780 |
D/D |
(103) |
4,641 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-02-12 |
4 |
D |
$187.51 |
$29,814 |
D/D |
(159) |
5,061 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
579 |
5,149 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-03-30 |
4 |
D |
$131.95 |
$133,797 |
D/D |
(1,014) |
7,449 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,402 |
8,463 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-04-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,010 |
8,459 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-04-03 |
4 |
D |
$113.31 |
$42,151 |
D/D |
(372) |
8,087 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-11-02 |
4 |
D |
$207.23 |
$185,471 |
D/D |
(895) |
9,198 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-11-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,006 |
9,198 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2020-11-04 |
4 |
S |
$214.14 |
$321,204 |
D/D |
(1,500) |
7,698 |
0 |
% |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
560 |
8,258 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-02-04 |
4 |
D |
$223.78 |
$41,847 |
D/D |
(187) |
8,071 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-02-12 |
4 |
D |
$238.26 |
$42,887 |
D/D |
(180) |
8,472 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
581 |
8,565 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-03-27 |
4 |
D |
$251.58 |
$198,748 |
D/D |
(790) |
9,786 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,104 |
10,576 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-05-06 |
4 |
S |
$276.55 |
$691,375 |
D/D |
(2,500) |
7,844 |
0 |
% |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-11-01 |
4 |
D |
$288.78 |
$259,324 |
D/D |
(898) |
8,953 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2021-11-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,007 |
9,851 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-02-02 |
4 |
D |
$273.18 |
$39,338 |
D/D |
(144) |
9,252 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
443 |
9,396 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
560 |
9,812 |
0 |
- |
|
| LH |
Laboratory Corp of Americ... |
CEO, Covance Drug Development |
• • – |
2022-02-04 |
4 |
D |
$277.48 |
$45,784 |
D/D |
(165) |
9,647 |
0 |
- |
|
41 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
